Class of 2025
For cutting-edge contributions to translational gastrointestinal cancer research, from the biological basis of disease to the clinical implementation of novel therapies and application of biomarkers in clinical trials; for the development of patient-derived xenograft models that have advanced therapies targeting the HER/ERK and PI3K signaling pathways in RAS/RAF-wild type and -mutant cancers; and for identifying predictive biomarkers to optimize treatment response and overcome therapeutic resistance.
*Full-length biography in development
[Institutional affiliations listed for Fellows reflect those held at the time of their induction into the AACR Academy.]